From Lipolytic Fragments to Incretin Agonists

The short version

Private Peptides is a briefing desk, not a store. It reads the published research on three peptides studied for metabolic regulation and weight management — AOD-9604, MOTS-c, and retatrutide — and reports it the way a clinician reads a chart: what the compound is, what the data show, what to watch, and what is still unknown.

The three sit on one arc, from fragment to agonist. AOD-9604 is a small piece of a natural hormone, engineered to do one narrow job. MOTS-c is a peptide the mitochondria themselves encode, tuning a cellular energy switch. Retatrutide is a fully synthetic, engineered molecule built to hit three receptors at once. Reading them in that order shows how far metabolic-peptide research has moved — and how unevenly the human evidence has kept pace.

This briefing does one job: state what was studied, in whom, and how far that evidence reaches, with a citation attached to every factual claim. It does not sell anything, does not give medical advice, and never lists a human dose except as reported inside a cited study.

What are research peptides?

Peptides are short chains of amino acids — smaller than proteins, built from the same twenty building blocks. The three compounds on this desk are structurally unrelated to one another but share a research classification: each is investigated for a role in energy balance, fat metabolism, or glucose handling, and each is sold in "research use only" form rather than as an approved medicine (retatrutide alone is also under active pharmaceutical development, in Phase 3 trials).

AOD-9604 is a synthetic fragment of a natural hormone. MOTS-c is derived from a sequence the human mitochondrial genome already encodes. Retatrutide is a fully engineered, fatty-acid-modified peptide with no natural counterpart. None of the three is approved by the FDA or any regulator for over-the-counter or self-directed human use. Where this briefing reports a dose, it reports the dose used in a specific cited study — never a recommendation for any individual.

The frame: from lipolytic fragments to incretin agonists

The organizing question on this desk is how directly a molecule intervenes in metabolism, and how far the human proof has caught up.

• AOD-9604 sits at one end: a single fragment of growth hormone, narrowly targeted at fat cells, with a large preclinical literature and a human obesity program that did not beat placebo ^[3].
• MOTS-c sits in the middle: a mitochondrial-signaling peptide that reaches into cellular energy regulation via AMPK and casein kinase 2, with a rich mechanistic record but no completed human efficacy trial — current human data are observational biomarker associations, not interventional outcomes ^[9].
• Retatrutide sits at the far end: a fully engineered triple-receptor agonist with a structured Phase 2 clinical program and weight-loss figures — up to roughly 24% body weight at 48 weeks — larger than any other incretin agent published to date ^[16].

That progression — fragment, endogenous signal, engineered agonist — is why these three sit together. Compare them directly on mechanism, evidence stage, and the single caution that matters most for each.

How this briefing reads the evidence

Every page on this desk follows the same structure a clinician uses to read an unfamiliar chart: what it is (mechanism and identity), what is shown (the actual trial or lab record, cited), what to watch (documented cautions and unresolved risk), and what is unknown (the honest gap between the data available and the claims circulating about it).

Where community reports exist — people describing their own experience with a compound in research-use forums — this desk carries them, clearly labeled as anecdotal, not clinical evidence, and never attached to a dose. Where no such reports exist in a citable form, as with MOTS-c, this desk says so rather than inventing a consensus. Every reference lives on one shared references page, numbered and linked back to source.